SLC5A2 and heart failure: Recently, the DELIVER23 and EMPEROR-Preserved24,25 trials showed reductions in composite cardiovascular death and heart failure events in patients with mildly reduced or preserved ejection fraction, supporting the use of the SGLT2 inhibitors in this patient population26,27.